Xia Peng

发表

Enhancing the cellular anti-proliferation activity of pyridazinones as c-met inhibitors using docking analysis.

Youhong Hu, M. Geng, Dong Lu, 2015, European journal of medicinal chemistry.

Design, Synthesis, and Pharmacological Evaluation of Novel Multisubstituted Pyridin-3-amine Derivatives as Multitargeted Protein Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer.

Hong Liu, M. Zheng, M. Geng, 2017, Journal of medicinal chemistry.

Design, synthesis and biological evaluation of a series of novel 2-benzamide-4-(6-oxy-N-methyl-1-naphthamide)-pyridine derivatives as potent fibroblast growth factor receptor (FGFR) inhibitors.

M. Geng, Ruimin Huang, L. Xing, 2018, European journal of medicinal chemistry.

Design, synthesis and biological evaluation of c-Met kinase inhibitors bearing 2-oxo-1,2-dihydroquinoline scaffold.

Wei Zhang, M. Geng, Yingxia Li, 2016, Bioorganic & medicinal chemistry letters.

Investigation on the 1,6-naphthyridine motif: discovery and SAR study of 1H-imidazo[4,5-h][1,6]naphthyridin-2(3H)-one-based c-Met kinase inhibitors.

M. Geng, Jian-Ping Lin, Yong Wang, 2013, Organic & biomolecular chemistry.

Design and synthesis of novel benzo[d]oxazol-2(3H)-one derivatives bearing 7-substituted-4-enthoxyquinoline moieties as c-Met kinase inhibitors.

Youhong Hu, M. Geng, Dong Lu, 2016, European journal of medicinal chemistry.

Discovery of novel type II c-Met inhibitors based on BMS-777607.

Wei Zhang, M. Geng, Yingxia Li, 2014, European journal of medicinal chemistry.

The Novel RET Inhibitor SYHA1815 Inhibits RET-Driven Cancers and Overcomes Gatekeeper Mutations by Inducing G1 Cell-Cycle Arrest through c-Myc Downregulation

Yi Chen, Youhong Hu, Yan-fen Fang, 2021, Molecular Cancer Therapeutics.

Optimization of 1H-indazol-3-amine derivatives as potent fibroblast growth factor receptor inhibitors.

Yingxia Li, Dingding Gao, Jing Ai, 2017, Bioorganic & medicinal chemistry letters.

Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models

Yi Chen, Jian Ding, M. Geng, 2019, Journal of Experimental & Clinical Cancer Research.

Discovery of 10H-Benzo[b]pyrido[2,3-e][1,4]oxazine AXL Inhibitors via Structure-Based Drug Design Targeting c-Met Kinase.

Qiu-feng Liu, H. Su, Yin-chun Ji, 2022, Journal of medicinal chemistry.

18F-FDG PET as an imaging biomarker for the response to FGFR-targeted therapy of cancer cells via FGFR-initiated mTOR/HK2 axis

Hu Zhou, Ruimin Huang, Yuchen Jiang, 2022, Theranostics.

Discovery of novel 2-aminopyridine-3-carboxamides as c-Met kinase inhibitors.

Hualiang Jiang, Hong Liu, Zhongjie Liang, 2012, Bioorganic & medicinal chemistry.

Pyridazinone derivatives displaying highly potent and selective inhibitory activities against c-Met tyrosine kinase.

Youhong Hu, M. Geng, Dong Lu, 2016, European journal of medicinal chemistry.

Multisubstituted quinoxalines and pyrido[2,3-d]pyrimidines: synthesis and SAR study as tyrosine kinase c-Met inhibitors.

Yechun Xu, M. Geng, Qiu-feng Liu, 2012, Bioorganic & medicinal chemistry letters.

Discovery of 6-(difluoro(6-(4-fluorophenyl)-[1,2,4]triazolo[4,3-b][1,2,4]triazin-3-yl)methyl)quinoline as a highly potent and selective c-Met inhibitor.

Yechun Xu, M. Geng, Qiu-feng Liu, 2016, European journal of medicinal chemistry.

Synthesis and structure-activity relationship study of pyrazolo[3,4-d]pyrimidines as tyrosine kinase RET inhibitors.

M. Geng, Hongchun Liu, Yin-chun Ji, 2017, Bioorganic & medicinal chemistry letters.

Design and optimization of a series of 1-sulfonylpyrazolo[4,3-b]pyridines as selective c-Met inhibitors.

Jian Ding, M. Geng, B. Xiong, 2015, Journal of medicinal chemistry.

Design and synthesis of 3,3'-biscoumarin-based c-Met inhibitors.

F. Nan, M. Geng, Lin-qian Yu, 2014, Organic & biomolecular chemistry.

A divergent approach to benzylisoquinoline-type and oxoaporphine alkaloids via regioselective direct ring metalation of alkoxy isoquinolines

Wei Zhang, S. Ley, M. Geng, 2015 .

DCLAK11, a multi-tyrosine kinase inhibitor, exhibits potent antitumor and antiangiogenic activity in vitro

Min Huang, Jian Ding, Hong Liu, 2015, Acta Pharmacologica Sinica.

Novel 2,4-Diarylaminopyrimidine Analogues (DAAPalogues) Showing Potent c-Met/ALK Multikinase Inhibitory Activities.

Yi Chen, M. Geng, Yin-chun Ji, 2014, ACS medicinal chemistry letters.

Polymeric immunoglobulin receptor promotes tumor growth in hepatocellular carcinoma

Min Huang, Yi Chen, Jian Ding, 2017, Hepatology.

Anthraquinone Derivatives as Potent Inhibitors of c-Met Kinase and the Extracellular Signaling Pathway.

Hualiang Jiang, Hong Liu, M. Zheng, 2013, ACS medicinal chemistry letters.

Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models

Yi Chen, Jian Ding, M. Geng, 2019, Journal of experimental & clinical cancer research : CR.

The Secretome Engages STAT3 to Favor a Cytokine-rich Microenvironment in Mediating Acquired Resistance to FGFR Inhibitors

Yi Chen, Jian Ding, M. Geng, 2018, Molecular Cancer Therapeutics.

c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors

Min Huang, Yi Chen, Jian Ding, 2016, Clinical Cancer Research.

Discovery of a new series of imidazo[1,2-a]pyridine compounds as selective c-Met inhibitors

Dong-mei Zhao, M. Geng, B. Xiong, 2016, Acta Pharmacologica Sinica.

Discovery of novel 2,4-diarylaminopyrimidine analogues (DAAPalogues) showing potent inhibitory activities against both wild-type and mutant ALK kinases.

Jian Ding, M. Geng, Zilan Song, 2015, Journal of medicinal chemistry.

SOMCL-863, a novel, selective and orally bioavailable small-molecule c-Met inhibitor, exhibits antitumor activity both in vitro and in vivo.

Min Huang, Jian Ding, M. Geng, 2014, Cancer letters.

DW14383 is an irreversible pan-FGFR inhibitor that suppresses FGFR-dependent tumor growth in vitro and in vivo

Jian Ding, Yin-chun Ji, W. Duan, 2020, Acta Pharmacologica Sinica.

Discovery and SAR study of c-Met kinase inhibitors bearing an 3-amino-benzo[d]isoxazole or 3-aminoindazole scaffold.

M. Geng, Yin-chun Ji, Qizheng Yao, 2015, Bioorganic & medicinal chemistry.

Novel tetracyclic benzo[b]carbazolones as highly potent and orally bioavailable ALK inhibitors: design, synthesis, and structure-activity relationship study.

Jian Ding, M. Geng, L. Xing, 2015, European journal of medicinal chemistry.

Design, synthesis and pharmacological evaluation of 2-(thiazol-2-amino)-4-arylaminopyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.

Jian Ding, M. Geng, Yin-chun Ji, 2014, European journal of medicinal chemistry.

Structural Optimization of Fibroblast Growth Factor Receptor Inhibitors for Treating Solid Tumors.

Xutong Li, M. Geng, Hong Liu, 2023, Journal of medicinal chemistry.

Design, synthesis and biological evaluation of pyrazolo[3,4-d]pyridazinone derivatives as covalent FGFR inhibitors

Hualiang Jiang, Hong Liu, M. Zheng, 2020, Acta pharmaceutica Sinica. B.

Discovery of novel Ponatinib analogues for reducing KDR activity as potent FGFRs inhibitors.

Youhong Hu, M. Geng, Dong Lu, 2017, European journal of medicinal chemistry.

SOMCL-085, a novel multi-targeted FGFR inhibitor, displays potent anticancer activity in FGFR-addicted human cancer models

Wei-ren Liu, Yinghong Shi, Zhen-Bin Ding, 2017, Acta Pharmacologica Sinica.

Discovery of pyrrolo[2,3-d]pyrimidine derivatives as potent Axl inhibitors: Design, synthesis and biological evaluation.

M. Geng, Yin-chun Ji, W. Duan, 2021, European journal of medicinal chemistry.

Design, Synthesis, and Pharmacological Evaluation of Biaryl-Containing PD-1/PD-L1 Interaction Inhibitors Bearing a Unique Difluoromethyleneoxy Linkage.

M. Geng, L. Xing, Bo Liu, 2021, Journal of medicinal chemistry.

Novel 5-(benzyloxy)pyridin-2(1H)-one derivatives as potent c-Met inhibitors.

Weiliang Zhu, Hualiang Jiang, Hong Liu, 2013, Bioorganic & medicinal chemistry letters.

Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells.

Liang Liu, Yin-chun Ji, E. Leung, 2017, MedChemComm.

Design, synthesis and biological evaluation of pyrazolylaminoquinazoline derivatives as highly potent pan-fibroblast growth factor receptor inhibitors.

Jingwei Shao, M. Geng, Chen Wang, 2016, Bioorganic & medicinal chemistry letters.

Simm530, a novel and highly selective c-Met inhibitor, blocks c-Met-stimulated signaling and neoplastic activities

Jian Ding, M. Geng, Wei-ren Liu, 2016, Oncotarget.

Discovery of potent 1H-imidazo[4,5-b]pyridine-based c-Met kinase inhibitors via mechanism-directed structural optimization.

M. Geng, Y. Long, Yingming Yao, 2015, Bioorganic & medicinal chemistry letters.

Laeviganoids A-T, ent-Clerodane-Type Diterpenoids from Croton laevigatus.

J. Yue, Qun-fang Liu, Bin-Shan Zhou, 2023, Journal of natural products.

SYK-mediated epithelial cell state is associated with response to c-Met inhibitors in c-Met-overexpressing lung cancer

M. Geng, Xuchao Zhang, Zuoquan Xie, 2023, Signal transduction and targeted therapy.

Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models

Yi Chen, Jian Ding, M. Geng, 2017, Molecular Cancer Therapeutics.

Evaluation of Deuterium-Labeled JNJ38877605: Pharmacokinetic, Metabolic, and in Vivo Antitumor Profiles.

W. Duan, Jing Ai, Xia Peng, 2018, Chemical research in toxicology.

Further SAR studies on 3,5-diamino-7-trifluoromethylquinolines as highly potent tyrosine kinase c-Met inhibitors: efforts to correct hERG inhibition

Yi Chen, M. Geng, Zhaobing Gao, 2012 .

Discovery and optimization of a series of 3-substituted indazole derivatives as multi-target kinase inhibitors for the treatment of lung squamous cell carcinoma.

M. Geng, B. Xiong, Yuchen Jiang, 2019, European journal of medicinal chemistry.

SAF-189s, a potent new-generation ROS1 inhibitor, is active against crizotinib-resistant ROS1 mutant-driven tumors

Jian Ding, Yan-fen Fang, M. Geng, 2020, Acta pharmacologica Sinica.

SAF-189s, a potent new-generation ROS1 inhibitor, is active against crizotinib-resistant ROS1 mutant-driven tumors

Jian Ding, Yan-fen Fang, M. Geng, 2020, Acta Pharmacologica Sinica.

Discovery of Novel c-Met Inhibitors Bearing a 3-Carboxyl Piperidin-2-one Scaffold

Wei Zhang, M. Geng, Yin-chun Ji, 2014, Molecules.

Simm530, a novel and highly selective c-Met inhibitor, blocks c-Met-stimulated signaling and neoplastic activities

Jian Ding, M. Geng, Yin-chun Ji, 2016, Oncotarget.

Discovery of 3-Aminopyrazole Derivatives as New Potent and Orally Bioavailable AXL Inhibitors.

Licheng Zhou, H. Hur, Zhen Wang, 2022, Journal of medicinal chemistry.

Design, Synthesis, and Biological Evaluation of Novel Imidazo[1,2-a]pyridine Derivatives as Potent c-Met Inhibitors.

X. Chen, Hong Liu, M. Geng, 2015, ACS medicinal chemistry letters.

Synthesis of triazolotriazine derivatives as c-Met inhibitors

Jian Ding, Yin-chun Ji, W. Duan, 2020, Molecular Diversity.

Design, synthesis and biological evaluation of novel FGFR inhibitors bearing an indazole scaffold.

Wei Zhang, M. Geng, S. Ren, 2015, Organic & biomolecular chemistry.

Structure-based drug discovery of novel fused-pyrazolone carboxamide derivatives as potent and selective AXL inhibitors

Yu Zhou, Chunpu Li, Yin-chun Ji, 2023, Acta pharmaceutica Sinica. B.